In a notice recently posted on its website, the Office of the U.S. Trade Representative (“USTR”) has announced that it is extending 99 expiring China 301 tariff exclusions on medical-care and/or COVID response products. The exclusions on the products in question had been previously extended through March 31, 2021. The USTR has decided to further extend these exclusions through September 30, 2021 in light of the continuing efforts to combat COVID-19. A list of the products at issue can be found in our prior update on the subject (https://www.gdlsk.com/ustr-extends-certain-china-301-exclusions-and-designates-additional-exclusions-for-the-period-january-1-march-31-2021/?highlight=china%20301%20exclusions%20%22March%2031%2C%202021%22).
No further actions with respect to China 301 exclusions have been announced. However, the USTR indicates in its notice that it may continue to consider further extensions and/or additional modifications as appropriate.
Please do not hesitate to contact us with any questions regarding the status of any particular China 301 exclusion, as well as mitigation strategies and potential refund opportunities – including by means of potential claims in the U.S. Court of International Trade with respect to List 3 and List 4 items.
